- Home
- GLUE
as 07-26-2024 4:00pm EST
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 217.7M | IPO Year: | 2021 |
| Target Price: | $12.25 | AVG Volume (30 days): | 258.1K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.44 - $8.84 | Next Earning Date: | 08-08-2024 |
| Revenue: | $1,064,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 149.73% |
Stock Insider Trading Activity of Monte Rosa Therapeutics Inc. (GLUE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dunn Edmund | GLUE | Principal Accounting Officer | Jul 5 '24 | Sell | $3.83 | 1,610 | $6,166.46 | 13,944 | SEC Form 4 |
| Dunn Edmund | GLUE | Principal Accounting Officer | Jun 3 '24 | Sell | $4.04 | 1,207 | $4,875.80 | 15,554 | SEC Form 4 |
Latest Monte Rosa Therapeutics Inc. News
GLUE Breaking Stock News: Dive into GLUE Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
GlobeNewswire
a month ago
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
GlobeNewswire
a month ago
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Reuters
2 months ago
Japan's service sector mood hits nearly 2-year low in May
Compare GLUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLUE Monte Rosa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.